Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics (Nasdaq: SLN) reported second quarter 2026 results, highlighting progress in its siRNA pipeline and lower operating losses for the period ended June 30, 2026. Cash and cash equivalents were $72.1 million. Revenue was $0 versus $224,000 in the second quarter of 2025.
Research and development expenses decreased to $9.1 million from $17.6 million year over year, mainly due to completion of zerlasiran Phase 3 readiness in 2025 and reduced personnel costs. General and administrative expenses declined to $4.7 million from $5.1 million. Net loss narrowed to $12.3 million, or $0.09 per share, compared with $27.4 million, or $0.19 per share.
According to the company, key business milestones included Phase 1 and 2 advances for divesiran in polycythemia vera, Phase 1 data for SLN312 (AZD1705) under the AstraZeneca collaboration showing favorable safety and durable ANGPTL3 and lipid reductions, and preclinical progress on SLN365 and SLN098 toward potential IND filings in 2027.
Silence Therapeutics (Nasdaq: SLN) announced an investor conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera. The event is scheduled for Monday, August 10, 2026 at 8:00 a.m. EDT.
Investors can access the event via a dedicated conference call registration link and a separate webcast link, with a replay to be made available in the Investors section of the company website. Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapies using its mRNAi GOLD platform across rare and common diseases.
Silence Therapeutics (Nasdaq: SLN) reported follow-up Phase 1 SANRECO data for divesiran in 21 phlebotomy-dependent polycythemia vera patients at EHA 2026.
Phlebotomies fell from 80 in the prior six months to 5 on treatment and 4 in 16-week follow-up, with median 287 days to first phlebotomy among 14 patients, symptom score improvements, and a favorable safety profile. Phase 2 Q6W/Q12W topline data are expected in August 2026.
Silence Therapeutics (Nasdaq: SLN), a clinical-stage biotech developing siRNA therapies, will join an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.
A live and archived webcast will be available in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN), a clinical-stage siRNA therapeutics company, announced that Chief Medical Officer Curtis Rambaran, MD, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. A live webcast and archived replay will be available in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q1 2026 results and program updates on May 7, 2026. Key operational items: SANRECO Phase 2 divesiran topline results remain on-track for August 2026, and Phase 1 abstracts for divesiran and SLN312 (AZD1705) were accepted for EHA and EAS 2026 congresses in June and May. Financial highlights: cash, cash equivalents and short-term investments $70.1M, R&D expenses $9.1M, G&A $7.0M, and net loss $15.0M for Q1 2026. Total shares outstanding: 141,703,840.
Silence Therapeutics (Nasdaq: SLN) reported Q4 and full-year 2025 results and business updates on March 5, 2026. Key highlights: topline Phase 2 SANRECO results for divesiran expected 3Q 2026, AstraZeneca will not advance SLN312 beyond Phase 1 and rights revert, and cash totaled $85.1M at year-end.
Full‑year 2025 collaboration revenue fell to $0.6M from $43.3M in 2024; net loss widened to $88.6M ($0.63/share) with R&D and G&A broadly stable.
Silence Therapeutics (NASDAQ: SLN) announced leadership changes effective December 14, 2025. Craig Tooman, who served as President and CEO and a board member since 2022, agreed by mutual consent to end his employment effective 14 December 2025. Iain Ross, the company chairman, will lead on an interim basis with immediate effect. James Ede Golightly, a former non-executive director, was re-appointed to the board. The company said it is in robust health both financially and operationally, and an additional US-based board appointment is anticipated in due course.
Silence Therapeutics (Nasdaq: SLN) said management will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT). The event will be available via a live webcast and an archived replay will be posted afterward in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q3 2025 results and business updates on November 6, 2025. Key highlights include completion of SANRECO Phase 2 enrollment for divesiran in polycythemia vera (48 phlebotomy-dependent patients) and anticipation of topline results in 3Q 2026. The company reported $102.2 million in cash, cash equivalents and short-term investments as of September 30, 2025, which management expects will fund operations into 2028. Q3 operating figures: R&D $20.5M, G&A $5.8M (down $1.9M YoY), and net loss $21.0M (improved from $35.5M a year earlier).